(Q44330585)

2 December 2017

0 references

Targeting opioid signaling in Crohn's disease: new therapeutic pathways (English)

1 reference

2 December 2017

1 reference

Ian S Zagon

1

1 reference

2 December 2017

Patricia J McLaughlin

series ordinal

2

1 reference

2 December 2017

publication date

1 October 2011

1 reference

Expert Review of Gastroenterology & Hepatology

2 December 2017

published in

1 reference

2 December 2017

volume

5

1 reference

2 December 2017

issue

5

1 reference

2 December 2017

page(s)

555-558

1 reference

New global map of Crohn's disease: Genetic, environmental, and socioeconomic correlations.

2 December 2017

cites work

1 reference

The costs of Crohn's disease in the United States and other Western countries: a systematic review

21 January 2018

1 reference

Pathogenesis of postoperative recurrence in Crohn's disease

21 January 2018

1 reference

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis

21 January 2018

1 reference

Role of neuropeptides in inflammatory bowel disease

21 January 2018

1 reference

The biology of the opioid growth factor receptor (OGFr)

21 January 2018

1 reference

Opioid receptors in the gastrointestinal tract

21 January 2018

1 reference

Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation.

21 January 2018

1 reference

Absence of preproenkephalin increases the threshold for T cell activation

21 January 2018

1 reference

Increased brain size and cellular content in infant rats treated with an opiate antagonist

21 January 2018

1 reference

Low-dose naltrexone therapy improves active Crohn's disease

21 January 2018

1 reference

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial

21 January 2018

1 reference

The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation

21 January 2018

1 reference

B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases

21 January 2018

1 reference

T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases

21 January 2018

1 reference

Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease

21 January 2018

1 reference

Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region

21 January 2018

1 reference

Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function

21 January 2018

1 reference

Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors

21 January 2018

1 reference

Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EGH.11.62

1 reference

2 December 2017

1 reference